Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
InsideTracker launched Terra, an AI platform that integrates wearable data, blood biomarkers, and health apps to deliver personalized recommendations for wellness and healthcare businesses. The shift reflects growing consumer demand for evidence-based outcomes rather than generic wellness claims, reshaping how the industry validates health interventions.
A strategic partnership between Deep Science Ventures and Medicines Discovery Catapult targets the blood-brain barrier as a systemic bottleneck limiting neurological drug delivery. Over 40% of the global population faces neurological conditions, yet the ability to transport therapeutics across this selective barrier remains the primary constraint, not the therapeutic discovery itself.
Elecoglipron (AZD5004/ECC5004), an oral once-daily GLP-1 receptor agonist developed by Eccogene and AstraZeneca, will present Phase 1b and Phase 2b clinical trial data at the American Diabetes Association Scientific Sessions in June 2026. The candidate targets weight loss and type 2 diabetes management with the practical advantage of no food or water restrictions.
Augustine Therapeutics will present preclinical data on an HDAC6 inhibitor for heart failure with preserved ejection fraction at the American Diabetes Association conference. The selective HDAC6 inhibitor represents a mechanistic approach to a prevalent cardiometabolic phenotype where ejection fraction remains normal despite functional impairment.
Corsair Pharma's transdermal patch delivered stable treprostinil levels over 24 hours with minimal fluctuation in early human trials, demonstrating pharmacokinetic performance comparable to injectable alternatives. This delivery method addresses a significant clinical gap in pulmonary hypertension treatment by reducing dosing frequency and injection burden while maintaining therapeutic consistency.
HeartSciences launched MyoVista Insights 1.3 with an AI-ECG Algorithm Marketplace, integrating FDA-cleared algorithms like Bunkerhill Health's ejection fraction detector into a cloud-native platform accessible to primary care through large health systems. This infrastructure democratizes advanced cardiac signal interpretation across clinical settings and establishes a scalable commercial model for third-party algorithm deployment.
Grip strength correlates strongly with longevity and serves as a marker of systemic health—muscle function, cardiovascular integrity, metabolic capacity—but does not itself drive longer life. The confusion between correlation and causation has led wellness influencers to oversell grip training as a direct longevity intervention when it is, in fact, a measurable signal of underlying physiological robustness.
Scribe Therapeutics has gained regulatory clearance to test STX-1150, a CRISPR-based therapy designed to suppress the PCSK9 gene in the liver and achieve durable LDL cholesterol reduction from a single treatment. This approach addresses a critical adherence gap: most people struggle to maintain lifelong cholesterol medication, creating a window of unprotected cardiovascular risk that conventional drugs fail to close.
Muse cells, a naturally occurring stem cell population enriched from mesenchymal stem cell populations, demonstrate three key characteristics—pluripotency, intrinsic homing to damaged tissues, and immune tolerance—that address longstanding obstacles in translating stem cell therapies to clinical outcomes. Early clinical studies suggest these cells may overcome manufacturing complexity, delivery failures, and poor cell survival that have limited traditional regenerative medicine approaches.
HAYA Therapeutics has initiated Phase 1 dosing of HTX-001, an antisense oligonucleotide targeting WISPER RNA to reprogram cardiac fibroblasts and reduce pathological fibrosis in heart failure. Preclinical data support reductions in cardiac fibrosis and functional improvements, with the trial progressing from healthy volunteers to patients with nonobstructive hypertrophic cardiomyopathy.
CellProthera is advancing ProtheraCytes, a CD34+ stem cell therapy, toward Phase 3 trials in post-infarction patients with the goal of preventing progression to heart failure. The approach delivers cells directly to the scar border zone via catheter, potentially offering earlier myocardial tissue repair than existing pharmacological or device-based interventions.
Plozasiran (REDEMPLO), an RNA interference therapy for familial chylomicronemia syndrome, has reached early commercial traction with approximately 180 patients treated and 83% median triglyceride reduction sustained over two years. This represents a distinct mechanistic approach to severe hypertriglyceridemia — addressing hepatic APOC3 production directly — with clinical efficacy and safety data that support its positioning as an alternative to competing inhibitors.